

## Appointment of Non-Executive Director

**PERTH, Australia, 23<sup>rd</sup> October 2017:** Phylogica Limited (ASX:PYC) (**Phylogica** or the **Company**), developer of a leading intracellular drug delivery platform technology, is pleased to announce the appointment of Mr Sahm Nasserri as Non-Executive Director for the replacement of current Non-Executive Director Dr Rick Kendall who has taken the decision to step down from the Board to concentrate on his other business commitments with Kite Pharma.

Mr Nasserri is currently a Director in Global Strategy and Marketing of HPV Vaccines at Merck & Co based in New York, USA. He started at Merck in the Australian subsidiary where he was Strategy and Business Development lead, reporting to the Managing Director and sitting on the local country leadership team.

Prior to joining Merck, Sahm was a management consultant with McKinsey & Company based in the Sydney office. During his 4 years at McKinsey, Sahm was involved in leading Strategy and Operations programs across several clients in healthcare, pharma, telecommunications, retail and mining. He has broad strategy, marketing, commercial deal-making and policy experience in the healthcare space across Asia Pacific and the US.

Sahm holds an MBA through a combined program at Columbia University in New York and the London Business School and has a Bachelors in Chemical Engineering (Hons) from the University of New South Wales.

Phylogica CEO Stephanie Unwin says Mr Nasserri brings significant strategic and commercial Pharma experience onto the Phylogica Board.

“Mr Nasserri’s expertise will be important to us as we validate and commercialise the value of our technology platform, expanding the reach of biological drugs to the previously undruggable intracellular environment,” she said.

“We have been very fortunate to have Dr Kendall’s significant expertise assisting us with our drug discovery efforts for the time he was on our Board and we wish him all the best in this very busy period for him at Kite Pharma.”

Following the above Board changes the Board of Phylogica now comprises:

Stephanie Unwin – Executive Chair and Chief Executive Officer

Dr Robert Hayes – Executive Director and Chief Scientific Officer

Prof. Paul Watt – Non-Executive Director

Dr Bernard Hockings – Non-Executive Director

Dr Rohan Hockings (Alternate for Dr Bernard Hocking)

Sahm Nasserri – Non-Executive Director

## ENDS

For further information, please contact:

### INVESTORS

Stephanie Unwin  
CEO  
[stephanieu@phylogica.com](mailto:stephanieu@phylogica.com)  
0411 132 287

### MEDIA

Ben Walsh  
WE Buchan  
[bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)  
0411 520 01

### About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and Genetech.

### Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

[www.phylogica.com](http://www.phylogica.com)